Dr. Bart Rijnders is associate professor in infectious diseases at the university hospital Erasmus MC in Rotterdam, the Netherlands. He studied medicine and defended his PhD on catheter-related infections at the University of Leuven in Belgium.
His research focus is on infections in the immunocompromised host, in particular patients with HIV or with haematological disease. He has a special interest in clinical studies on the treatment of HIV, side effects of cART, the diagnosis and treatment of sexually transmitted diseases among which acute HCV among HIV+ patients. In haematology patients his research addresses the prevention, diagnosis and treatment of infections in particular invasive fungal infections and catheter-related infections.
Recently completed studies on HIV and HCV addressed issues like the assumed equivalence of FTC and 3TC, the risk of TDF renal toxicity during MRP4 inhibitor use, acute HCV therapy with boceprevir/peg/rbv, safety and efficacy of a nevirapine to rilpivirine switch and the efficacy of dolutegravir monotherapy as maintenance therapy (DOMONO study).
Ongoing multicenter studies are addressing, short-course DAA for acute HCV (DAHHS2 study), the safety of TAF in HIV patients with TDF renal toxicity (BACTAF study), 8 weeks of sofosbuvir+ledipasvir for HCV gen4 (Hepned001), the incidence of HCV among HIV+MSM in the DAA era in the Netherlands and immune reconstitution inflammatory syndrome in the integrase inhibitor era (RISING study).
Studies in patients with haematological disease are addressing the role of DNA amplification to detect azole resistance in culture negative invasive aspergillosis (AZORMAN study) and influenza and aspergillus coinfection in ICU patients (CIA study).
When not working, Bart enjoys al kinds of endurance sports like inline skating, or cross-country skying.